Literature DB >> 8732665

Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.

T G Ram1, S P Ethier.   

Abstract

Amplification and overexpression of the c-erbB-2 gene in 21MT-2 and 21MT-1 human breast carcinoma cells results in progressively elevated levels of constitutively tyrosine-phosphorylated p185erbB-2 and is associated with progressive insulin-like growth factor (IGF) and combined IGF/epidermal growth factor (EGF) independence in culture. In addition, the neu differentiation factor/heregulins (HRGs), a family of ligands that activate p185erbB-2 through direct binding to erbB-3 or erbB-4, are potent mitogens for various nonneoplastic mammary epithelial cells and carcinoma cell lines in the absence of both IGF and EGF in culture. We have investigated the ability of ligand induction with HRGs or the constitutive activation of p185erbB-2 in the 21MT breast carcinoma cells to induced the recruitment of phosphatidylinositol 3-kinase (PI3K) by p185erbB-2 and erbB-3. HRG was found to potently induce the recruitment of the M(r) 85,000 regulatory subunit of PI3K by phosphotyrosine proteins in both nonneoplastic H16N-2 mammary epithelial cells (which express normal c-erbB-2 levels) and in the 21MT-2 and 21MT-1 cell lines, which were all isolated from a single patient with intraductal and invasive ductal carcinoma of the breast and express c-erbB-3 but not c-erbB-4 in culture. The activation of PI3K in these cells was also associated with high-level mitogenic responsiveness to HRG, as well as the IGF/EGF-independent proliferation of the 21MT cell lines in culture. The recruitment of PI3K by phosphotyrosine protein during ligand-induced activation, or that seen constitutively in the 21MT tumor cells, did not involve detectable tyrosine phosphorylation of p85. The HRG-induced recruitment of p85 and the constitutive recruitment of p85 in the 21MT cell lines involved direct association with both p185erbB-2 and erbB-3, although greater levels were recruited directly by erbB-3. Wortmannin, a potent inhibitor of PI3K enzymatic activity, also blocked the autonomous proliferation of the 21MT cells, and this effect was reversible in long-term cultures. These data indicate that PI3K may be an especially important mediator of HRG-induced proliferation in mammary epithelial cells and is involved in the autonomous proliferation of growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732665

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  13 in total

Review 1.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.

Authors:  N J Hellyer; K Cheng; J G Koland
Journal:  Biochem J       Date:  1998-08-01       Impact factor: 3.857

3.  Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells.

Authors:  D K Biswas; A P Cruz; E Gansberger; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1.

Authors:  Gunamani Sithanandam; George T Smith; Janet R Fields; Laura W Fornwald; Lucy M Anderson
Journal:  Am J Respir Cell Mol Biol       Date:  2005-07-29       Impact factor: 6.914

Review 5.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

6.  Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein.

Authors:  H H Kim; U Vijapurkar; N J Hellyer; D Bravo; J G Koland
Journal:  Biochem J       Date:  1998-08-15       Impact factor: 3.857

Review 7.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

8.  Inhibitory role of alpha 6 beta 4-associated erbB-2 and phosphoinositide 3-kinase in keratinocyte haptotactic migration dependent on alpha 3 beta 1 integrin.

Authors:  Edith Hintermann; Martin Bilban; Andrew Sharabi; Vito Quaranta
Journal:  J Cell Biol       Date:  2001-04-30       Impact factor: 10.539

Review 9.  Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?

Authors:  M J Fry
Journal:  Breast Cancer Res       Date:  2001-06-28       Impact factor: 6.466

Review 10.  Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer.

Authors:  J Donovan; J Slingerland
Journal:  Breast Cancer Res       Date:  2000-02-21       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.